BILTHOVEN, Netherlands--(BUSINESS WIRE)--Factory CRO, a leading global contract research organization focused on medical devices and IVDs, has announced the acquisition of MileStone Research Organization. MileStone, located in San Diego, specializes in clinical research and reimbursement solutions for the medical device and biologics industries.
“The merger with MileStone is an important step in building Factory’s operational strength and service range in North America,” said Dirk Meijer, M.D., Ph.D., Factory CEO. “MileStone is an excellent fit therapeutically, as well as culturally, and complements our existing U.S. operations in Austin, Texas, and Princeton, N.J. Milestone’s extensive expertise in orthopedics, neurological and IVD clinical trials, as well as their reimbursement and site management service offerings, is a fantastic value-add for all our clients.”
“The combination of Factory and MileStone is good for everyone,” said Kevin Liang, Ph.D., founder of MileStone Research Organization. “Our specialization in clinical and regulatory affairs, as well as reimbursement for innovative technologies, aligns us perfectly with Factory. Factory’s full-service clinical offerings and extensive knowledge of the European regulatory environment will greatly expand our reach. The mutual commitment of both organizations to provide world-class solutions and superior client support will continue to motivate the company’s growth moving forward.”
Factory performs safety, efficacy and clinical economics studies as well as quality-of-life and post-marketing studies globally for medical device, IVD and drug-device combination products. Since 1992, the company has completed more than 450 projects in Class II and III medical devices in a wide range of therapeutic areas for some of the top global medical device manufacturers.
For more information, visit factory-cro.com.
About Factory CRO
Factory is a leading, full-service
contract research organization focused on the management of clinical
studies for medical devices, IVDs, biologics and device-drug combination
products internationally. Founded in 1992, the business offers a full
suite of trial management services to its global client base across a
broad range of therapeutic areas, including orthopedic, cardiovascular,
dermatology and aesthetics.
